EPZ031686
Based on 6 publication(s) in Google Scholar
EPZ031686 is an potent and orally active SMYD3 inhibitor and with an IC50 value of 3 nM. EPZ031686 can be used for cancer research.
For research use only. We do not sell to patients.
- Purity: 99.46%
- CAS No.: 2095161-11-6
- Formula: C26H34ClF3N4O4S
- Molecular Weight:591.09
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Transcription Factor-Targeted Library
HY-L090
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) EPZ031686
More
Customer Validation & Images
-
WB
All Histone Methyltransferase Isoforms
More
Biological Activity
|
SMYD3 3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
36 nM
Compound: EPZ031686
|
Inhibition of human SMYD3 expressed in HEK293T/17 cells using FLAG-tagged MEKK2 as substrate incubated for 30 mins in low air flow area followed by incubation for 24 hrs at 37 degC by Western blot analysis
Inhibition of human SMYD3 expressed in HEK293T/17 cells using FLAG-tagged MEKK2 as substrate incubated for 30 mins in low air flow area followed by incubation for 24 hrs at 37 degC by Western blot analysis
|
[PMID: 26985287] |
Pharmacokinetic Analysis in Male CD-1 mice[1]
| Route | Dose (mg/kg) | CL (mL/min/kg) | CLr (mL/min/kg) | Vss (L/kg) | tmax (h) | tmax (h) | Cmax (ng/mL) | AUClast (ng·h/mL) | AUCINF_obs (ng·h/mL) |
| i.v. | 1 | 27 | 5.3 | 2.3 | 1.7 | / | / | 603 | 616 |
| p.o. | 5 | / | / | / | 2.7/td> | 0.89 | 345 | 1281 | 1479 |
| p.o. | 50 | / | / | / | 2.2 | 1.3 | 4693 | 21158 | 21170 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2095161-11-6
-
Appearance Solid
-
Molecular Weight 591.09
-
Formula C26H34ClF3N4O4S
-
Color White to light yellow
-
SMILES
O=C(C1)NC2=C1C=C(C(N[C@@H]3C[C@H]4N(S(CC5CCN(CCCC(F)(F)F)CC5)(=O)=O)[C@H](CC4)C3)=O)C(Cl)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
SMYD3-PARP16 axis accelerates unfolded protein response and mediates neointima formation. [Abstract]2021 May;11(5):1261-1273. PMID: 34094832 -
Sci Adv
The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer. [Abstract]2023 Nov 15;9(46):eadi5921. PMID: 37976356 -
J Transl Med
Loss of histone methyltransferase Smyd3 triggers WAT browning and adaptive thermogenesis via enhancing PPARγ expression in a H4K20me3-dependent manner. [Abstract]2025 Oct 1;23(1):1041. PMID: 41034941 -
Diabetes
Molecular Mechanisms of Human Pancreatic Islet Dysfunction Under Overnutrition Metabolic Stress. [Abstract]2025 Oct 1;74(10):1825-1838. PMID: 40773375 -
Eur J Med Chem
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3. [Abstract]2022 Dec 5:243:114683. PMID: 36116234 -
Aging
2020 Nov 3;12(21):21423-21445. PMID: 33144524
EPZ031686 purchased from MedChemExpress. Usage Cited in: Aging. 2020 Nov 3;12(21):21423-21445. [Abstract]
EPZ031686 (20 μM) reverses Ang II-induced PARP16 and RAECs senescence. Inhibition of Smyd3 could downregulate protein level of PARP16, together with reduced ER stress and senescence markers.
Solvent & Solubility
DMSO : 35 mg/mL (59.21 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.75 mg/mL (2.96 mM); Clear solution
This protocol yields a clear solution of ≥ 1.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.75 mg/mL (2.96 mM); Clear solution
This protocol yields a clear solution of ≥ 1.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6918 mL | 8.4589 mL | 16.9179 mL | 42.2947 mL |
| 5 mM | 0.3384 mL | 1.6918 mL | 3.3836 mL | 8.4589 mL | |
| 10 mM | 0.1692 mL | 0.8459 mL | 1.6918 mL | 4.2295 mL | |
| 15 mM | 0.1128 mL | 0.5639 mL | 1.1279 mL | 2.8196 mL | |
| 20 mM | 0.0846 mL | 0.4229 mL | 0.8459 mL | 2.1147 mL | |
| 25 mM | 0.0677 mL | 0.3384 mL | 0.6767 mL | 1.6918 mL | |
| 30 mM | 0.0564 mL | 0.2820 mL | 0.5639 mL | 1.4098 mL | |
| 40 mM | 0.0423 mL | 0.2115 mL | 0.4229 mL | 1.0574 mL | |
| 50 mM | 0.0338 mL | 0.1692 mL | 0.3384 mL | 0.8459 mL |
Powered by Bioz